You appear to be using an older version of Internet Explorer. We suggest you upgrade your browser for the best viewing experience. Upgrade to a Modern Browser
The CJEU issued on 21 March 2019 its judgment in the Abraxis C-443/17 case. The full text of the judgment can be found here.
The CJEU held that SPCs are not available for new formulations of old active ingredients. Whilst the CJEU’s conclusions regarding the unavailability of SPCs for new formulations of old active ingredients will not be popular with innovator companies, there will no doubt be relief that the CJEU did not follow the earlier recommendation of the Advocate General (reported here) to overturn Neurim.